Skip to main content
Advertisement

Main menu

  • Home
  • Content
    • Current Issue
    • Accepted Manuscripts
    • Article Preview
    • Past Issue Archive
    • Video Articles
    • AJNR Case Collection
    • Case of the Week Archive
    • Case of the Month Archive
    • Classic Case Archive
  • Special Collections
    • Low-Field MRI
    • Alzheimer Disease
    • ASNR Foundation Special Collection
    • Photon-Counting CT
    • AJNR Awards
    • View All
  • Multimedia
    • AJNR Podcasts
    • AJNR SCANtastic
    • Trainee Corner
    • MRI Safety Corner
    • Imaging Protocols
  • For Authors
    • Submit a Manuscript
    • Submit a Video Article
    • Submit an eLetter to the Editor/Response
    • Manuscript Submission Guidelines
    • Statistical Tips
    • Fast Publishing of Accepted Manuscripts
    • Graphical Abstract Preparation
    • Imaging Protocol Submission
    • Author Policies
  • About Us
    • About AJNR
    • Editorial Board
    • Editorial Board Alumni
  • More
    • Become a Reviewer/Academy of Reviewers
    • Subscribers
    • Permissions
    • Alerts
    • Feedback
    • Advertisers
    • ASNR Home

User menu

  • Alerts
  • Log in

Search

  • Advanced search
American Journal of Neuroradiology
American Journal of Neuroradiology

American Journal of Neuroradiology

ASHNR American Society of Functional Neuroradiology ASHNR American Society of Pediatric Neuroradiology ASSR
  • Alerts
  • Log in

Advanced Search

  • Home
  • Content
    • Current Issue
    • Accepted Manuscripts
    • Article Preview
    • Past Issue Archive
    • Video Articles
    • AJNR Case Collection
    • Case of the Week Archive
    • Case of the Month Archive
    • Classic Case Archive
  • Special Collections
    • Low-Field MRI
    • Alzheimer Disease
    • ASNR Foundation Special Collection
    • Photon-Counting CT
    • AJNR Awards
    • View All
  • Multimedia
    • AJNR Podcasts
    • AJNR SCANtastic
    • Trainee Corner
    • MRI Safety Corner
    • Imaging Protocols
  • For Authors
    • Submit a Manuscript
    • Submit a Video Article
    • Submit an eLetter to the Editor/Response
    • Manuscript Submission Guidelines
    • Statistical Tips
    • Fast Publishing of Accepted Manuscripts
    • Graphical Abstract Preparation
    • Imaging Protocol Submission
    • Author Policies
  • About Us
    • About AJNR
    • Editorial Board
    • Editorial Board Alumni
  • More
    • Become a Reviewer/Academy of Reviewers
    • Subscribers
    • Permissions
    • Alerts
    • Feedback
    • Advertisers
    • ASNR Home
  • Follow AJNR on Twitter
  • Visit AJNR on Facebook
  • Follow AJNR on Instagram
  • Join AJNR on LinkedIn
  • RSS Feeds

AJNR at ASNR25 | Join us at BOOTH 312 and more. Check out our schedule

EditorialEDITORIALS

Tissue-Specific MR Imaging in Multiple Sclerosis

À. Rovira
American Journal of Neuroradiology August 2009, 30 (7) 1277-1278; DOI: https://doi.org/10.3174/ajnr.A1777
À. Rovira
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • Responses
  • References
  • PDF
Loading

Conventional MR imaging techniques (cMRI), such as T2-weighted sequences and gadolinium-enhanced T1-weighted sequences, which are highly sensitive for detecting multiple sclerosis (MS) plaques, have become established as the most important paraclinical tool for diagnosing MS, as well as for understanding the natural history of the disease and monitoring the efficacy of experimental treatments. In fact, cMRI metrics have become common primary end points in phase II immunomodulatory drug therapy trials.1 However, a possible role of cMRI metrics as surrogate end points in phase III trials has been disclaimed because of the poor correlation between cMRI metrics and the clinical disease course, particularly disability progression, which is driven by the neurodegenerative component of the disease.2

Explanations for this clinical-radiologic discrepancy include inappropriate clinical rating, neglect of spinal cord involvement, underestimation of damage to the normal-appearing brain tissue (both white and gray matter), and compensation by cortical adaptation.3 However, one of the major contributors to this paradox is the lack of pathologic specificity of T2-weighted imaging, which provides only a dichotomous type of information, that is, it simply discriminates between MS focal lesions and normal-appearing white matter but not between the type and degree of the underlying pathologic substrates (edema, inflammation, demyelination, remyelination, reactive gliosis, and axonal loss)4 that contribute differently to the development of permanent disability.

In the last 15 years, a huge effort has been made by the MR imaging research community to overcome the limited pathologic specificity of cMRI by developing new MR imaging techniques that selectively measure the more destructive aspects of MS pathology and monitor the reparative mechanisms, such as T1 hypointense lesions, quantitative analysis of global and regional brain volume, magnetization transfer MR imaging, diffusion-weighted MR imaging, and proton MR spectroscopy. These techniques appear to be more sensitive biomarkers for measuring the pathologic processes underlying the progression of clinical disability (demyelination and axonal loss).5

The first MR imaging−based measure proposed as a specific marker of focal MS lesions with severe tissue destruction was T1 hypointense lesions.6 However, these so-called T1 “black holes” may have a different pathologic substrate depending, in part, on the lesion age. Hypointensity is present in ≤80% of recently formed lesions and likely represents marked edema, with or without myelin destruction or axonal loss. In most cases, acute (“wet”) black holes become isointense or slightly hypointense within a few months, as inflammatory activity abates, edema resolves, and reparative mechanisms such as remyelination become active, resulting in partial axonal preservation. Less than 40% evolve into persisting or chronic black holes,7,8 which correlate pathologically with permanent demyelination and severe axonal loss. Several immunomodulatory drugs (glatiramer acetate, interferon beta, and natalizumab) reduce the progression of acute gadolinium-enhancing lesions into persistent or chronic black holes, supporting a certain neuroprotective effect of these treatments by disrupting the advancement of tissue destruction.9-11

However this MR imaging−based measure has some important drawbacks that limit its use as a true marker of severe irreversible tissue damage. One of the most important limitations is the fact that the definition of what constitutes a black hole is arbitrary, highly dependent on the MR imaging technique used, and based on visual inspection. Therefore, it remains a challenge to accurately discriminate between slightly/moderately and strongly hypointense T1 lesions, which reflect different degrees of remyelination and axonal loss. This pathologic heterogeneity has been demonstrated by postmortem studies12 and by in vivo MR spectroscopy and magnetization transfer imaging studies, which have shown that tissue damage is extremely variable in individual black holes.13,14 Consequently, patients with similar black hole lesion volume may have different degrees of disability depending on the nature of the histopathologic substrate.

For this reason, new ways of measuring black holes have been recently developed, such as the T1 hypointensity ratio15 and the one proposed in this issue of American Journal of Neuroradiology by Riva et al.16 These authors assessed the ability of a new MR imaging technique, which they call “tissue-specific imaging” to selectively identify black holes with the longest T1 values, which likely reflect lesions with severe demyelination and axonal loss. The results of this study are promising and provide data indicating that this technique could be a sensitive method for detecting and quantifying hypointense T1 lesions with more advanced tissue destruction. Nevertheless, additional studies are required before new MR imaging−based measures can be considered markers of disease severity and progression in MS or surrogate markers of remyelination and neuronal protection in clinical trials. These additional studies should demonstrate their reproducibility, sensitivity to disease evolution and treatment changes, and their value in reflecting and predicting the accumulation of irreversible disability.17

All these necessary efforts are especially important nowadays, when there is a growing interest in developing neuroprotective agents in MS, which consequently demands new imaging strategies for achieving and monitoring myelin repair and axonal loss.18

References

  1. ↵
    Sormani MP, Bonzano L, Roccatagliata L, et al. Magnetic resonance imaging as a potential surrogate for relapse in multiple sclerosis: a meta-analytic approach. Ann Neurol 2009;65:270–77
  2. ↵
    Goodin DS. Magnetic resonance imaging as a surrogate outcome measure of disability in multiple sclerosis: have we been overly harsh in our assessment? Ann Neurol 2006;59:597–05
    CrossRefPubMed
  3. ↵
    Barkhof F. The clinico-radiological paradox in multiple sclerosis revisited. Curr Opin Neurol 2002;15:239–45
    CrossRefPubMed
  4. ↵
    Barkhof F, Bruck W, De Groot CJ, et al. Remyelinated lesions in multiple sclerosis: magnetic resonance image appearance. Arch Neurol 2003;60:1073–81
    CrossRefPubMed
  5. ↵
    Arnold DL. Evidence for neuroprotection and remyelination using imaging techniques. Neurology 2007;68 (suppl 3):S83–S90
    Abstract/FREE Full Text
  6. ↵
    Van Walderveen MA, Barkhoff F, Hommes OR, et al. Correlating MRI and clinical disease activity in multiple sclerosis: relevance of hypointense lesions on short-TR/short-TE (T1-weighted) spin-echo images. Neurology 1995;45:1684–90
    Abstract/FREE Full Text
  7. ↵
    Bagnato F, Jeffries N, Richert ND, et al. Evolution of T1 black holes in patients with multiple sclerosis imaged monthly for 4 years. Brain. 2003;126 (Pt 8):1782–89
    Abstract/FREE Full Text
  8. ↵
    Zivadinov R. Can imaging techniques measure neuroprotection and remyelination in multiple sclerosis? Neurology 2007;68 (suppl 3):S72–S82
    Abstract/FREE Full Text
  9. ↵
    Filippi M, Rovaris M, Rocca MA, et al, and the European/Canadian Glatiramer Acetate Study Group. Glatiramer acetate reduces the proportion of new MS lesions evolving into “black holes.” Neurology 2001;57:731–33
    Abstract/FREE Full Text
  10. Dalton CM, Miszkiel KA, Barker GJ, et al. Effect of natalizumab on conversion of gadolinium enhancing lesions to T1 hypointense lesions in relapsing multiple sclerosis. J Neurol 2004;251:407–13
    CrossRefPubMed
  11. ↵
    Bagnato F, Gupta S, Richert ND, et al. Effects of interferon beta-1b on black holes in multiple sclerosis over a 6-year period with monthly evaluations. Arch Neurol 2005;62:1684–88
    CrossRefPubMed
  12. ↵
    Van Walderveen MA, Kamphorst W, Scheltens P, et al. Histopathologic correlates of hypointense lesions on T1-weighted spin-echo MRI in multiple sclerosis. Neurology 1998;50:1282–88
    Abstract/FREE Full Text
  13. ↵
    Li BS, Moriarty DM, Regal J, et al. In vivo 3D 1H MRS of T1-hypointense lesions in relapsing-remitting multiple sclerosis. In: Proceedings of the International Society for Magnetic Resonance in Medicine, Glasgow, Scotland, UK, April 21–27,2001
  14. ↵
    Barkhof F, Karas GB, van Walderveen MA. T1 hypointensities and axonal loss. Neuroimaging Clin N Am 2000;10:739–52
    PubMed
  15. ↵
    Fritz D, Dwyer MG, Quadros C, et al. T1 intensity differences to normal appearing white matter in hypointense lesions on MRI are related to clinical status in multiple sclerosis. J Neurol 2006;253:104–26
  16. ↵
    Riva M, Ikonomidou VN, Ostuni JJ, et al. Tissue-specific imaging as a robust methodology to differentiate in vivo T1 black holes with advanced multiple sclerosis-induced damage. AJNR Am J Neuroradiol 2009;30:1394–401
    Abstract/FREE Full Text
  17. ↵
    Miller DH. Biomarkers and surrogate outcomes in neurodegenerative disease: lessons from multiple sclerosis. NeuroRx 2004;1:284–94
    Abstract/FREE Full Text
  18. ↵
    Rice C, Scolding N. Strategies for achieving and monitoring myelin repair. J Neurol 2007;254:275–83
    CrossRefPubMed
  • American Society of Neuroradiology
PreviousNext
Back to top

In this issue

American Journal of Neuroradiology: 30 (7)
American Journal of Neuroradiology
Vol. 30, Issue 7
August 2009
  • Table of Contents
  • Index by author
Advertisement
Print
Download PDF
Email Article

Thank you for your interest in spreading the word on American Journal of Neuroradiology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Tissue-Specific MR Imaging in Multiple Sclerosis
(Your Name) has sent you a message from American Journal of Neuroradiology
(Your Name) thought you would like to see the American Journal of Neuroradiology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Cite this article
À. Rovira
Tissue-Specific MR Imaging in Multiple Sclerosis
American Journal of Neuroradiology Aug 2009, 30 (7) 1277-1278; DOI: 10.3174/ajnr.A1777

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
0 Responses
Respond to this article
Share
Bookmark this article
Tissue-Specific MR Imaging in Multiple Sclerosis
À. Rovira
American Journal of Neuroradiology Aug 2009, 30 (7) 1277-1278; DOI: 10.3174/ajnr.A1777
del.icio.us logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Purchase

Jump to section

  • Article
    • References
  • Info & Metrics
  • Responses
  • References
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • Double Inversion Recovery Sequence of the Cervical Spinal Cord in Multiple Sclerosis and Related Inflammatory Diseases
  • Crossref (2)
  • Google Scholar

This article has been cited by the following articles in journals that are participating in Crossref Cited-by Linking.

  • Double Inversion Recovery Sequence of the Cervical Spinal Cord in Multiple Sclerosis and Related Inflammatory Diseases
    I. Riederer, D. C. Karampinos, M. Settles, C. Preibisch, J. S. Bauer, J. F. Kleine, M. Muhlau, C. Zimmer
    American Journal of Neuroradiology 2015 36 1
  • Knowledge and awareness on Balo's disease among dental students
    Bathala Ananya, Vishnupriya Veeraraghavan, S. Kavitha, J. Selvaraj, R. Gayathri
    Journal of Advanced Pharmaceutical Technology & Research 2022 13 Suppl 1

More in this TOC Section

  • Teaching Lessons by MR CLEAN
  • Coffee Houses and Reading Rooms
  • Comeback Victory
Show more EDITORIALS

Similar Articles

Advertisement

Indexed Content

  • Current Issue
  • Accepted Manuscripts
  • Article Preview
  • Past Issues
  • Editorials
  • Editor's Choice
  • Fellows' Journal Club
  • Letters to the Editor
  • Video Articles

Cases

  • Case Collection
  • Archive - Case of the Week
  • Archive - Case of the Month
  • Archive - Classic Case

More from AJNR

  • Trainee Corner
  • Imaging Protocols
  • MRI Safety Corner

Multimedia

  • AJNR Podcasts
  • AJNR Scantastics

Resources

  • Turnaround Time
  • Submit a Manuscript
  • Submit a Video Article
  • Submit an eLetter to the Editor/Response
  • Manuscript Submission Guidelines
  • Statistical Tips
  • Fast Publishing of Accepted Manuscripts
  • Graphical Abstract Preparation
  • Imaging Protocol Submission
  • Evidence-Based Medicine Level Guide
  • Publishing Checklists
  • Author Policies
  • Become a Reviewer/Academy of Reviewers
  • News and Updates

About Us

  • About AJNR
  • Editorial Board
  • Editorial Board Alumni
  • Alerts
  • Permissions
  • Not an AJNR Subscriber? Join Now
  • Advertise with Us
  • Librarian Resources
  • Feedback
  • Terms and Conditions
  • AJNR Editorial Board Alumni

American Society of Neuroradiology

  • Not an ASNR Member? Join Now

© 2025 by the American Society of Neuroradiology All rights, including for text and data mining, AI training, and similar technologies, are reserved.
Print ISSN: 0195-6108 Online ISSN: 1936-959X

Powered by HighWire